期刊文献+

替尼泊苷诱导Tca8113细胞凋亡及细胞周期阻滞的实验观察

Teniposide inducing apoptosis and G2/M phase arrest of Tca8113 cells
下载PDF
导出
摘要 目的:检测替尼泊苷(teniposide,VM-26)的体外抗肿瘤增殖效果并探索其作用机制。方法:以不同浓度的VM-26体外作用Tca8113细胞,应用MTT方法、流式细胞仪、透射电镜和荧光染色等分别检测细胞的生长抑制率、凋亡率及细胞周期分布。使用SAS6.12软件进行单因素方差分析。结果:VM-26和CDDP对Tca8113细胞的半数抑制浓度分别为0.35μg/ml和1.1μg/ml。透射电镜观察细胞形态发生典型的凋亡表现,5.0μg/ml和0.15μg/ml的VM-26作用72h,细胞凋亡率分别为81.01%和17.38%,而细胞周期则分别被阻滞在S期和G2/M期。结论:VM-26可以显著诱导口腔鳞癌细胞凋亡并抑制细胞生长,不同剂量的VM-26对口腔鳞癌细胞周期阻滞的阶段不同。 PURPOSE:The present study is designed to identify quantitatively the in vitro effect of VM-26 against oral squamous cell carcinoma Tca8113 and to explore the underlying mechanism. METHODS: Human tongue squamous cell carcinoma cell line Tca8113 was used as subject. Cells were incubated with VM-26 of various concentrations for a variety of time spans. Cisplatin (CDDP) was employed as a control agent. MTT assay was used to assess the inhibition of cell growth by VM-26. Flow cytometer (FCM), transmission electron microscope (TEM) and fluorescence staining were employed for determining the apoptotic rate of cells induced by VM-26. Cell cycle distribution of Tca8113 cells incubated with VM-26 was examined through flow cytometer assay. SAS 6.12 was used for one-way ANOVA. RESULTS: The IC50 of VM-26 against Tca8113 cells was 0.35μg/ml and that of CDDP was 1.1μg/ml. The changes in morphology and ultrastructure of Tca8113 cells were observed using fluorescence microscope and TEM, and apoptotic morphological feature could be found in the nucleus. Apoptotic rate of Tca8113 cells incubated with VM-26 of 5.0μg/ml for 72 hours was 81.01% and cell cycle appeared was arrested at S phase. However, exposed to VM-26 of 0.15μg/ml for 72 hours, Tca8113 cells in the G2/M phase increased from 12.75% to 98.71%, while the apoptotic rate of these cells was 17.38% and far below than that of cells treated with VM-26 of 5.0μg/ml. CONCLUSION: VM-26 could significantly induce apoptosis of oral squamous cell carcinoma cells and inhibit cell growth. There may be another pathway to induce apoptosis of oral squamous cell carcinoma cells except for G2/M phase arrest. Supported by National Natural Science Foundation of China (30300388, 30171014, 30330580) and Research Grant (No.036505013, 034107002) of Science and Technology Committee of Shanghai Municipality.
出处 《上海口腔医学》 CAS CSCD 2005年第3期267-272,共6页 Shanghai Journal of Stomatology
基金 国家自然科学基金(30300388 30171014 30330580) 上海市科学技术委员会科研资助基金(036505013 034107002)
关键词 口腔鳞癌 替尼泊苷 顺铂 凋亡 细胞周期 Oral squamous cell carcinoma Teniposide Cisplatin Apoptosis Cell cycle
  • 相关文献

参考文献13

  • 1Bepler G, O'Briant K. In vitro chemosensitivity testing of human non-small cell lung cancer cell lines [J]. Anticancer Res, 1998,18(A): 3181-3185.
  • 2陈万涛,周晓健,徐骎,郭伟,林李嵩.口腔颌面肿瘤活检标本对化疗药物敏感性的研究[J].中华口腔医学杂志,2002,37(6):404-407. 被引量:14
  • 3陈万涛,周晓健,徐骎,郭伟,竺涵光,叶为民.替尼泊甙对口腔鳞癌化疗敏感性的体外研究[J].中华口腔医学杂志,2003,38(6):441-443. 被引量:5
  • 4Morse-Gaudio M, Risley MS. Topoisomerase Ⅱ expression and VM-26 induction of DNA breaks during spermatogenesis in Xenopus Laevis[J]. J Cell Sci, 1994, 107: 2887-2898.
  • 5Mo YY, Beck WT. DNA damage signals induction of Fas ligand in tumor cells[J]. Mol Pharmacol, 1999, 55: 216-222.
  • 6L JWoessner RD, Mattern MR, Mirabelli CK, et al. Proliferation-dependent and cell cycle-dependent differences in expression of the 170-kilodahon and 180-kilodalton forms of topoisomerase-Ⅱ in NIH 3T3 cells[J]. Cell Growth Differ,1991,2:209-214.
  • 7Nakopoulou L, Lazaris AC, Kavantzas N, et al. DNA topoisomerase Ⅱ-alpha immunoreaetivity as a marker of tumor aggressiveness in invasive breast eaneer[J]. Pathobiol, 2000, 68:137-143.
  • 8凤渝蓉,张洪福,孟刚,曹立宇.TopoⅡα及E-cad在口腔鳞状细胞癌中表达的意义[J].安徽医科大学学报,2002,37(6):441-443. 被引量:2
  • 9Heck MM, Earnshaw W. Topoisomerase Ⅱ, a specific marker for cell proliferation[J]. J Cell Biol, 1986, 103: 2569-2581.
  • 10Bruden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase Ⅱ and drugs targeted to the enzyme [J]. Biochimica et Biophysica Acta, 1998, 1400: 139-154.

二级参考文献16

  • 1邱蔚六.口腔颌面肿瘤的研究及诊治10年进展[J].耳鼻咽喉(头颈外科),1996,3(1):57-61. 被引量:8
  • 2Berger JM, Gamblin S J, Harrison SC et al. Structure and mechanism of DNA topoisomerase 1Ⅱ . Nature, 1996; 379(6562): 225-232
  • 3Yabuki N, Sasano H, Kato K. Immunohistochemical study of DNA topoisomerase 1Ⅱ in human gastric disorders. Am J Pathol, 1996;149(3) :997~1007
  • 4Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol, 1995;7(5) :619~627
  • 5Shiozaki H, Oka H, Inoue M et al. E-cadherin mediated adhesion system in cancer cells. Cancer, 1996;77(8): 1605~1613
  • 6Ohashi Y, Sasano H, Yamaki H et al. Topoisomerase Ⅱ alpha expression in esophageal squamous cell carcinoma. Anticancer Res,1999; 19(3A): 1873~1880
  • 7Stathopoulos GP, Kapranos N, Manolopoulos L et al. Topoisomerase Ⅱ alpha expression in squamous cell carcinomas of the head and neck. Anticancer Res, 2000; 20(1 A): 177~182
  • 8Schipper JH, Frixen UH, Behrens J et al. E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor differentiation and lymph node metastasis. Cancer Res, 1991;5.1(23) :6328
  • 9徐建明,宋三泰,汤仲明,江泽飞,周莉,刘晓晴,李彦博,杨奕静.MTT体外药敏试验指导下的乳癌预见性化疗[J].中华肿瘤杂志,1997,19(2):153-156. 被引量:43
  • 10苏剑敏,周逸平,徐薇苓,查锡良.E-钙粘蛋白在肿瘤中的表达与分化转移的关系[J].上海医科大学学报,2000,27(1):28-31. 被引量:6

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部